Genesis Biosystems, Inc.
Genesis Biosystems, Inc., headquartered in the United States, is a leading innovator in the medical device industry, specialising in advanced solutions for the healthcare sector. Founded in 2006, the company has established itself as a key player in the development of cutting-edge technologies for tissue regeneration and wound care. With a focus on products such as the innovative Genesis® System, Genesis Biosystems offers unique, evidence-based solutions that enhance patient outcomes and streamline clinical workflows. The company’s commitment to quality and innovation has earned it a strong market position, recognised for its contributions to improving healthcare delivery. As it continues to expand its operational reach, Genesis Biosystems remains dedicated to advancing the field of regenerative medicine.
DitchCarbon Score
How does Genesis Biosystems, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genesis Biosystems, Inc.'s score of 28 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Genesis Biosystems, Inc.'s reported carbon emissions
In 2022, Genesis Biosystems, Inc. reported total carbon emissions of approximately 46,887,000,000 kg CO2e, comprising 41,202,000,000 kg CO2e from Scope 1 emissions and 5,685,000,000 kg CO2e from Scope 2 emissions. The Scope 1 emissions included 201,000,000 kg CO2e from mobile combustion, 19,523,000,000 kg CO2e from process emissions, and 8,346,000,000 kg CO2e from stationary combustion. The Scope 2 emissions were primarily from purchased electricity, amounting to 179,000,000 kg CO2e. Comparatively, in 2021, the company emitted approximately 41,491,000,000 kg CO2e, with Scope 1 emissions at 36,388,000,000 kg CO2e and Scope 2 emissions at 5,103,000,000 kg CO2e. This indicates a slight increase in total emissions from 2021 to 2022. Genesis Biosystems has not disclosed any specific reduction targets or initiatives, nor does it appear to have cascaded data from a parent organisation. The company has not reported on Scope 3 emissions, which typically encompass indirect emissions from the value chain. Overall, while the company has substantial emissions, it currently lacks defined climate commitments or reduction strategies.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Scope 1 | 40,448,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 |
| Scope 2 | 10,450,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Genesis Biosystems, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
